Option Care Health (NASDAQ:OPCH) Releases FY 2024 Earnings Guidance

Option Care Health (NASDAQ:OPCH) updated its FY 2024 earnings guidance on Monday. The company provided EPS guidance of 1.550-1.590 for the period, compared to the consensus EPS estimate of 1.210. The company issued revenue guidance of $5.0 billion-$5.0 billion, compared to the consensus revenue estimate of $4.9 billion. Option Care Health also updated its FY 2025 guidance to 1.590-1.690 EPS.

Option Care Health Trading Up 11.7 %

NASDAQ:OPCH opened at $26.80 on Monday. The business’s 50-day simple moving average is $23.10 and its 200-day simple moving average is $27.69. Option Care Health has a fifty-two week low of $21.39 and a fifty-two week high of $34.63. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32. The stock has a market capitalization of $4.56 billion, a PE ratio of 22.52, a price-to-earnings-growth ratio of 2.43 and a beta of 1.31.

Analyst Ratings Changes

OPCH has been the subject of several research reports. Barrington Research lowered their price objective on shares of Option Care Health from $40.00 to $32.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. UBS Group initiated coverage on Option Care Health in a research note on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price target on the stock. The Goldman Sachs Group cut Option Care Health from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $38.00 to $27.00 in a research report on Monday, November 4th. Truist Financial cut their target price on Option Care Health from $41.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Bank of America cut shares of Option Care Health from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $43.00 to $29.00 in a research note on Wednesday, October 30th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $29.14.

Insider Buying and Selling

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. bought 43,000 shares of the firm’s stock in a transaction on Friday, November 8th. The shares were purchased at an average price of $22.54 per share, for a total transaction of $969,220.00. Following the completion of the transaction, the director now directly owns 326,334 shares in the company, valued at approximately $7,355,568.36. The trade was a 15.18 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.64% of the stock is currently owned by company insiders.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.